Targeting the B cell receptor pathway in chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M.Chronic lymphocytic leukemia.The New England journal of medicine 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F.The microenvironment in mature B-cell malignancies: a target for new treatment strategies.Blood 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Burger JA.Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology/the Education Program of the American Society of Hematology.Am Soc Hematol Educ Prog 2011;96–103.
   Google Scholar
• Stevenson FK, Caligaris-Cappio F.Chronic lymphocytic leukemia: revelations from the B-cell receptor.Blood 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.Blood 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Burger JA.Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.Seminars in cancer biology 2010;20:424–430.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, . Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Zent CS, LaPlant BR, Johnston PB, . The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.Cancer 2010;116:2201–2207.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, . CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.Proc Natl Acad Sci USA 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Tsubata T, Wienands J.B cell signaling.Introduction. Int Rev Immunol 2001;20:675–678.
   PubMedGoogle Scholar
• Reth M.Antigen receptors on B lymphocytes.Annu Rev Immunol 1992;10:97–121.
   PubMed Web of Science ®Google Scholar
• Shinohara H, Kurosaki T.Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling.Immunol Rev 2009;232:300–318.
   PubMed Web of Science ®Google Scholar
• Monroe JG.ITAM-mediated tonic signalling through pre-BCR and BCR complexes.Nature reviews. Immunology 2006;6:283–294.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, . SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.Blood 2008;111:2230–2237.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, . Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.British journal of haematology 2006;132:303–316.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, . Stereotyped B-cell receptors in one third of chronic lymphocytic leukemia: towards a molecular classification with implications for targeted therapeutic interventions.Blood 2012.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T.Syk tyrosine kinase required for mouse viability and B-cell development.Nature 1995;378:303–306.
   PubMed Web of Science ®Google Scholar
• Turner M, Mee PJ, Costello PS, . Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk.Nature 1995;378:298–302.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen G, Fecteau J, Coffey G, Prussak C, . Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis.ASH. Volume 641; 2011.
   Google Scholar
• Buchner M, Baer C, Prinz G, . Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.Blood 2010;115:4497–4506.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Coffey GP, Sinha U, . Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2012.
   Google Scholar
• Suljagic M, Longo PG, Bennardo S, . The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.Blood16:4894–4905.
   Google Scholar
• Braselmann S, Taylor V, Zhao H, . R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.J Pharmacol Exp Ther 2006;319:998–1008.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, . Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.Arthritis Rheum 2008;58:3309–3318.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology1999;17:1244.
   Google Scholar
• Giles FJ, Albitar M.Mammalian target of rapamycin as a therapeutic target in leukemia. Current molecular medicine2005;5:653–661.
   Google Scholar
• Decker T, Hipp S, Ringshausen I, . Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.Blood 2003;101:278–285.
   PubMed Web of Science ®Google Scholar
• Granziero L, Ghia P, Circosta P, . Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.Blood 2001;97:2777–2783.
   PubMed Web of Science ®Google Scholar
• Huang S, Shu L, Dilling MB, . Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1).Molecular cell 2003;11:1491–1501.
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Peschel C, Decker T.Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.Leukemia & lymphoma 2005;46:11–19.
   PubMed Web of Science ®Google Scholar
• Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C.A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.Annals of hematology 2009;88:221–227.
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, . The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.Science signaling 2010;3:ra60.
   Web of Science ®Google Scholar
• Cuni S, Perez-Aciego P, Perez-Chacon G, . A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18:1391–1400.
   Google Scholar
• Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG.The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.Blood 2008;111:846–855.
   PubMed Web of Science ®Google Scholar
• Niedermeier M, Hennessy BT, Knight ZA, . Isoform-selective phosphoinositide 3’-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.Blood 2009;113:5549–5557.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, . The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.Blood 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, . The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.Blood 2011;117:4323–4327.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, . Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.Blood 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, . CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110d Demonstrates Clinical Activity and Pharmacodynamic Effects in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.ASH. Volume 116; 2010.
   Google Scholar
• Sharman J, de Vos S, Leonard J, Furman R, . A Phase 1 Study of the Selective PI3K Inhibitor CAL-101 (GS-1101) in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL.ASH. Volume 642; 2011.
   Google Scholar
• Martin AL, Schwartz MD, Jameson SC, Shimizu Y.Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase.Journal of immunology 2008;180:2081–2088.
   PubMed Web of Science ®Google Scholar
• Edelman G, Bedell G, Shapiro SS, Pandya EL, Cwak C. . A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients with advanced malignancies.ASCO. Volume 28; 2010.
   Google Scholar
• Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, . Phase I Trial of SAR245408 (S08), a Pan-PI3K Inhibitor, in Patients with CLL and Lymphoma.ASH. Volume 623; 2011.
   Google Scholar
• Papadopoulos KP, Abrisqueta MD, Chambers G, . A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), an Orally Administered PI3K/mTOR Inhibitor in Patients with Lymphoma.Blood. 2011;118. Abstract 1608.
   Web of Science ®Google Scholar
• Lorusso P, Markman J, Tabernero R, Shazer L, Heath E, . A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors.ASCO. Volume27:15s; 2009.
   Google Scholar
• de Weers M, Brouns GS, Hinshelwood S, . B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.The Journal of biological chemistry 1994;269:23857–23860.
   PubMed Web of Science ®Google Scholar
• de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW.Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.Human molecular genetics 1994;3:161–166.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Blood 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, . Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Blood 2011.
   PubMed Web of Science ®Google Scholar
• Rooij MF, Kuil A, Geest CR, . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.Blood 2012.
   PubMed Web of Science ®Google Scholar
• Genevier HC, Hinshelwood S, Gaspar HB, . Expression of Bruton's tyrosine kinase protein within the B cell lineage.European journal of immunology 1994;24:3100–3105.
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, . Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.ChemMedChem 2007;2:58–61.
   PubMed Web of Science ®Google Scholar
• Burger JA, O’Brien S, Fowler N, Advani R, Sharman J, . The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies.ASH; 2010.
   Google Scholar
• O’Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, . The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study.ASH. Volume 642; 2011.
   Google Scholar
• Evans E, Tester P, Aslanian S, Chaturvedi P, Mazdiyasni H, . Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies.ASH. Volume 604; 2011.
   Google Scholar
• Chen L, Widhopf G, Huynh L, . Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.Blood 2002;100:4609–4614.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, . ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.Blood 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Matthews C, Catherwood MA, . ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).Blood 2006;107:3584–3592.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK.Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Guarini A, Chiaretti S, Tavolaro S, . BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells.Blood 2008;112:782–792.
   PubMed Web of Science ®Google Scholar
• Coscia M, Pantaleoni F, Riganti C, . IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2011;25:828–837.
   Google Scholar
• Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV.Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes.The Journal of experimental medicine 1993;177:1821–1826.
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, . High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.Blood 2009;113:3050–3058.
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV, . B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.Blood 2009;114:1029–1037.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.The New England journal of medicine 2011;365:2497–2506.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.Nature 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Quesada V, Conde L, Villamor N, . Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.Nature genetics 2012;44:47–52.
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar EC, Takvorian T, . Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17:2977–2986.
   PubMed Web of Science ®Google Scholar